Dalzanemdor

N/A

Report date: 2025/07/04 17:49:18
NME

Base Information

Drug NameDalzanemdor
Drug Alias NameSAGE-718
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor modulators
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsCognitive DysfunctionAlzheimer DiseaseDementia +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[5
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSage Therapeutics Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesSage Therapeutics Inc
Active IndicationsCognitive DysfunctionAlzheimer DiseaseDementia +[4
Inactive IndicationsHuntington Disease

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG